Co-Diagnostics CEO to Discuss Progress & Forecasts in a Lytham Partners’ Virtual Investors Conference Presentation on Tuesd...
November 30 2018 - 1:43PM
Business Wire
Co-Diagnostics, Inc. (Nasdaq: CODX), a diagnostics
company with a unique, patented platform for the development of
molecular diagnostic tests, announced today that it will discuss
the Company’s recent progress and upcoming sales expectations
on Tuesday, December 4, 2018 at 4:00 pm
ET (3:00 pm CT) in a Lytham Partners’ Virtual Investors
Conference Presentation. The presentation will be available online
with interested parties able to participate by following the
webcast links below at the time of the presentation.
The presentation will be conducted by Mr. Dwight Egan,
Chairman and Chief Executive Officer of the Company, and is
expected to consist of a Company progress update and review of
milestones reached in 2018, followed by the Company’s expectations
for near-term sales and questions from the audience. The event will
be moderated by Joe Diaz, managing partner at Lytham
Partners.
Event: Co-Diagnostics, Inc. Virtual Presentation and
Fireside Chat Date:
Tuesday, December 4, 2018
Time: 4 pm ET (3 pm CT; 2 pm MT; 1 pm PT)
Webcast:
By accessing the link here or
http://codiagnostics.com/investors/events-presentations/.
A replay of the presentation will be available on demand
following the conclusion of the live event.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular
diagnostics company with a patented diagnostic testing technology
and development platform that intends to manufacture and sell
reagents used for diagnostic tests that function via the detection
and/or analysis of nucleic acid molecules (DNA or RNA). The Company
also uses its proprietary technology to design specific tests to
locate genetic markers for use in industries other than infectious
disease and license the use of those tests to specific
customers.
Forward-Looking Statements:
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking
statements in this release include statements regarding the (i) use
of funding proceeds, (ii) expansion of product distribution, (iii)
acceleration of initiatives in liquid biopsy and SNP detection,
(iv) use of the Company’s liquid biopsy tests by laboratories, (v)
capital resources and runway needed to advance the Company’s
products and markets, (vi) increased sales in the near-term, (vii)
flexibility in managing the Company’s balance sheet, (viii)
anticipation of business expansion, and (ix) benefits in research
and worldwide accessibility of the CoPrimer technology and its
cost-saving and scientific advantages. Forward-looking statements
are subject to inherent uncertainties, risks and changes in
circumstances. Actual results may differ materially from
those contemplated or anticipated by such forward-looking
statements. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181130005457/en/
Company Contact:Andrew BensonCo-Diagnostics Investor
Relations801-438-1036investors@codiagnostics.com
Investor Contact:Joe Diaz, Robert Blum and Joe
DorameLytham Partners, LLC602-889-9700codx@lythampartners.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Sep 2023 to Sep 2024